| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥6.08B | +192.9% |
| Gross profit | ¥1.37B | — |
| Operating income | ¥0.87B | — |
| Net income | ¥0.75B | +352.9% |
| Gross margin | 22.5% | Net margin 12.3% |
| Revenue Q/Q | +55.8% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥4.71B | 77.5% |
| R&D | ¥0.11B | 1.8% |
| SG&A | ¥0.05B | 0.8% |
| Tax & other | ¥0.12B | 2.0% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
科拓生物 ・ 西域旅游 ・ 锋尚文化 ・ 美畅股份 ・ 蓝盾光电 ・ 卡倍亿 ・ 南大环境 ・ 大宏立 ・ 圣元环保 ・ 杰美特 ・ 康泰医学 ・ 欧陆通
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies